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The earliest studies in contrast echocardiography were re- 
ported from the University of Rochester in 1968 by Gramiak 
and Shah (I), who used indocyanine green as the contrast 
agent. Subsequently, many different agents were used for 
contrast echocardiography (2). During the past several 
years, contrast echocardiography has undergone dynamic 
changes through developments of new contrast agents and 
innovative methods. Although many of the older applica- 
tions of contrast have been largely replaced by Doppler 
echocardiography, various uses for left heart contrast, espe- 
cially myocardial perfusion imaging (3), have attracted in- 
creasing interest. 
Myocardial perfusion imaging by contrast echocardiog- 
raphy holds great promise for the evaluation of patients with 
coronary artery disease. However, it currently requires 
intracoronary or aortic root injections. Thus, myocardial 
contrast echocardiography will remain limited in scope un- 
less contrast agents and methods are developed that allow 
intravenous injection. The study by Smith et al. (4) in this 
issue of the Journal represents another step toward “nonin- 
vasive” left heart contrast echocardiography. 
Transpulmonary contrast agents. Major progress has 
been achieved in the development of new echo contrast 
agents capable of pulmonary transmission. It was apparent 
from early studies (5) that the source of ultrasound contrast 
was related to gaseous microbubbles. Initial contrast studies 
used the hand agitation technique to introduce microbubbles 
in various solutions. However, most of the hand-agitated 
microbubbles were trapped by the pulmonary vascular bed 
because they were too large to pass the capillary circulation 
and surface tension properties prevented persistence of the 
microbubbles small enough for capillary transit (6). With the 
development of sonication by Feinstein et al. (7), a useful 
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method for producing relatively uniform, small and more 
stable microbubbles, capable of transcapillary passage, be- 
came available. Cheirif et al. (8) demonstrated a physiologic 
transit time of sonicated Renografin-76 in a microvascular 
preparation, and Keller et al. (9) recently reported that 
sonicated albumin microbubbles behave as intravascular 
tracers of red blood cell flow in the microcirculation. 
Several studies (10-23) have shown contrast in the left 
heart chambers after right-sided pulmonary wedge or intra- 
venous injections of various echo contrast agents. Only a 
few of these studies (14,16,18) have noted myocardial con- 
trast after such injections. This myocardial opacification was 
not reproducible, dense or suitable for quantitative assess- 
ment of myocardial perfusion. 
With reports of commercial agents having known micro- 
bubble size and quantity such as Albunex [Molecular Bio- 
systems, Inc.] and, in this issue, SHU-508 [Schering], new 
prospects for contrast echocardiography and myocardial 
perfusion imaging are emerging. Recent reports (24,25) have 
shown the safety and reproducibility of contrast echocardio- 
graphic imaging of left heart chambers after intravenous 
injection of Albunex. Furthermore, myocardial perfusion 
imaging may be feasible after such injections (26). SHU-508, 
the new saccharide echo contrast agent reported in this issue 
by Smith et al. (4), seems to be capable of pulmonary 
transmission and to result in left heart contrast. This is 
exciting because the mechanism of microbubble generation 
and stabilization appears to be different from that occurring 
after high intensity sonication. Microbubbles created after 
high intensity sonication of albumin can be stable for weeks 
to months and probably have denatured albumin coats 
around them. The mechanism of microbubble creation asso- 
ciated with saccharide agents is proprietary but must be 
different: the microbubbles are generated by the physical 
and chemical reactions occurring when the saccharide pow- 
der is added to the diluent a few minutes before injection, 
and these microbubbles are transient. Probably the mecha- 
nism of biodegradation of the contrast agents is also dif- 
ferent: denatured albumin from Albunex is likely removed 
by the reticuloendothelial system whereas a saccharide 
crystal may dissolve over several minutes in the blood- 
stream. 
Clinical applications. Left ventricular contrast may be 
useful for the study of flow characteristics in the left heart 
and systemic circulation, enhancement of endocardial bor- 
ders and low intensity Doppler signals, automatic edge 
detection, quantitation of shunt and regurgitant lesions and 
calculation of left ventricular ejection fraction. Despite the 
recent progress and the approaching commercial introduc- 
tion of transpulmonary agents, the noninvasive assessment 
of regional myocardial perfusion continues to be limited by 
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the available contrast agents. Many problems have yet to be 
resolved and need to be studied further. These include the 
critical mass of material required to achieve a reproducible 
myocardial contrast effect, the effect of respiratory status on 
transpulmonary passage of the contrast agent and methods 
of correcting for the inherent disappearance rate of micro- 
bubbles after intravenous injections. Because agents are 
being developed that are capable of pulmonary transmission 
by different mechanisms, future research should focus on 
methods needed to assure safety and to achieve denser 
opacification and consistent and quantifiable myocardial 
contrast. 
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